News & Events

Biosion monoclonal antibody therapies to be featured at the American Association for Cancer Research (AACR) meeting 2022

April 6, 2022

Biosion Inc Biosion a global R amp D stage biotechnology company announced today the upcoming presentations of non-clinical data from its oncology pipeline including nbsp BSI- T nbsp anti-siglec- antibody nbsp and BSI- anti-SIRP antibody nbsp at the American Association for Cancer Research AACR [...]

LEARN MORE

Biosion licenses BSI-060T (anti-Siglec-15) to Pyxis Oncology

March 30, 2022

Pyxis Oncology will be responsible for development and commercialization of BSI- T now referred to as PYX- a fully human anti-Siglec- monoclonal antibody Biosion earns a million upfront license fee additional milestone payments and royalties on commercial sales to be earned upon advancement of [...]

LEARN MORE

Biosion, Inc. Appoints Joel Edwards, MBA, as Chief Business Officer

February 21, 2022

Newark DE U S and Nanjing China nbsp nbsp February nbsp nbsp Biosion Inc Biosion a global clinical stage biotechnology company today announced the appointment of Joel Edwards as chief business officer In this position he is responsible for strategic leadership over all aspects [...]

LEARN MORE

Biosion, Inc. Appoints Anthony Yeh, Ph.D., as Chief Strategy Officer and Head of China BD

January 3, 2022

Newark DE U S and Nanjing China nbsp January nbsp Biosion Inc Biosion a global clinical stage biotechnology company today announced the appointment of Dr Anthony Yeh to the position of Chief Strategy Officer and Head of China business development BD where he will [...]

LEARN MORE